Under the terms of the agreement, TG Therapeutics will make an up-front payment as well as make development and sales-based milestone payments and will pay a tiered single
The grant has been given to clinically advance Irofulven for the treatment of metastatic castration resistant prostrate cancer (mCRPC) by utilising a highly predictive biomarker for the drug
SuppreMol is involved in development of treatment options for autoimmune and allergic diseases. Besides owning and operating SuppreMol’s Munich operations, Baxter will also own SuppreMol’s complete early-stage development
CRPS is a condition characterised by severe pain in a limb, accompanied by autonomic, sensory, motor and trophic changes. In few patients, the chronic pain can lead to
Although the results from both placebo (36.5 mm improvement from baseline, p < 0.0001) and Tradipitant (40.5mm improvement from baseline, p < 0.0001) displayed significant and clinically meaningful
The acquisition includes assignment of certain patents and patent applications owned or controlled by the Swiss firm related to RNAi therapeutics. The deal also comprises of an exclusive
According to the company, the barcode on the overwrap is correct but the primary container barcode could be mislabeled with the barcode for Heparin Sodium 2000 USP units/1000mL
The two angiotensin-converting enzyme (ACE) inhibitors are approved by Health Canada and they will now be commercialized and manufactured locally by Valeant at its Laval, Quebec facility. Population
Under the deal, BMS will have an exclusive option to license and commercialize Prostvac, which is being developed to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
Imbruvica is approved for use in four indications to treat three different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom’s macroglobulinemia. AbbVie chairman
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.